Cell Reports-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2097970, encodeId=0397209e97070, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：20220428 submitted 20220506 under review 20220622 all reviews complete 20220623 major revision 20220822 revised 20221018 pre-accept 20221101 accept 整个投稿过程不快不慢，编辑态度很好，review意见专业，根据我的经验这个期刊算不上水刊，而且在国外认可度还不错，毕竟不靠发review拉分，唯一的就是版面费不便宜，cell press旗下，看好未来！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Tue Nov 01 23:47:24 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564653, encodeId=ccbd56465366, content=是么？控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高加州理工的工人 2018-05-29 05:21:00 发表: 我刚发一篇.说实话.这个期刊要求真心不高, beContent=控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd1b2506977, createdName=124af5d5m75暂无昵称, createdTime=Wed Dec 19 00:00:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188688, encodeId=af6d11886885a, content=审稿速度:3.0 偏重的研究方向：肝脏纤维化 经验分享：前段时间投了一次。两周后才送外审，接着外审一个半月被拒。感觉审稿较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f226485261, createdName=ms8000002038666433, createdTime=Thu Jan 27 21:35:31 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104788, encodeId=06841104e8854, content=摘要需要详细到什么程度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104787, encodeId=9e451104e87f7, content=撰写摘要有什么要点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2023-06-14 ms7000001335611101 来自天津

偏重的研究方向：医学;肿瘤
经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢

88 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2097970, encodeId=0397209e97070, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：20220428 submitted 20220506 under review 20220622 all reviews complete 20220623 major revision 20220822 revised 20221018 pre-accept 20221101 accept 整个投稿过程不快不慢，编辑态度很好，review意见专业，根据我的经验这个期刊算不上水刊，而且在国外认可度还不错，毕竟不靠发review拉分，唯一的就是版面费不便宜，cell press旗下，看好未来！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Tue Nov 01 23:47:24 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564653, encodeId=ccbd56465366, content=是么？控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高加州理工的工人 2018-05-29 05:21:00 发表: 我刚发一篇.说实话.这个期刊要求真心不高, beContent=控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd1b2506977, createdName=124af5d5m75暂无昵称, createdTime=Wed Dec 19 00:00:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188688, encodeId=af6d11886885a, content=审稿速度:3.0 偏重的研究方向：肝脏纤维化 经验分享：前段时间投了一次。两周后才送外审，接着外审一个半月被拒。感觉审稿较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f226485261, createdName=ms8000002038666433, createdTime=Thu Jan 27 21:35:31 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104788, encodeId=06841104e8854, content=摘要需要详细到什么程度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104787, encodeId=9e451104e87f7, content=撰写摘要有什么要点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-11-01 苦逼科研仔

审稿速度:2.0 | 投稿命中率:50.0
经验分享：20220428 submitted
20220506 under review
20220622 all reviews complete
20220623 major revision
20220822 revised
20221018 pre-accept
20221101 accept
整个投稿过程不快不慢，编辑态度很好，review意见专业，根据我的经验这个期刊算不上水刊，而且在国外认可度还不错，毕竟不靠发review拉分，唯一的就是版面费不便宜，cell press旗下，看好未来！

169 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2097970, encodeId=0397209e97070, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：20220428 submitted 20220506 under review 20220622 all reviews complete 20220623 major revision 20220822 revised 20221018 pre-accept 20221101 accept 整个投稿过程不快不慢，编辑态度很好，review意见专业，根据我的经验这个期刊算不上水刊，而且在国外认可度还不错，毕竟不靠发review拉分，唯一的就是版面费不便宜，cell press旗下，看好未来！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Tue Nov 01 23:47:24 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564653, encodeId=ccbd56465366, content=是么？控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高加州理工的工人 2018-05-29 05:21:00 发表: 我刚发一篇.说实话.这个期刊要求真心不高, beContent=控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd1b2506977, createdName=124af5d5m75暂无昵称, createdTime=Wed Dec 19 00:00:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188688, encodeId=af6d11886885a, content=审稿速度:3.0 偏重的研究方向：肝脏纤维化 经验分享：前段时间投了一次。两周后才送外审，接着外审一个半月被拒。感觉审稿较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f226485261, createdName=ms8000002038666433, createdTime=Thu Jan 27 21:35:31 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104788, encodeId=06841104e8854, content=摘要需要详细到什么程度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104787, encodeId=9e451104e87f7, content=撰写摘要有什么要点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2018-12-19 124af5d5m75暂无昵称

是么？控球后卫-姚明 2018-05-29 发表::
我刚发一篇.说实话.这个期刊要求真心不高加州理工的工人 2018-05-29 05:21:00 发表:
我刚发一篇.说实话.这个期刊要求真心不高

控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高

743 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2097970, encodeId=0397209e97070, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：20220428 submitted 20220506 under review 20220622 all reviews complete 20220623 major revision 20220822 revised 20221018 pre-accept 20221101 accept 整个投稿过程不快不慢，编辑态度很好，review意见专业，根据我的经验这个期刊算不上水刊，而且在国外认可度还不错，毕竟不靠发review拉分，唯一的就是版面费不便宜，cell press旗下，看好未来！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Tue Nov 01 23:47:24 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564653, encodeId=ccbd56465366, content=是么？控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高加州理工的工人 2018-05-29 05:21:00 发表: 我刚发一篇.说实话.这个期刊要求真心不高, beContent=控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd1b2506977, createdName=124af5d5m75暂无昵称, createdTime=Wed Dec 19 00:00:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188688, encodeId=af6d11886885a, content=审稿速度:3.0 偏重的研究方向：肝脏纤维化 经验分享：前段时间投了一次。两周后才送外审，接着外审一个半月被拒。感觉审稿较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f226485261, createdName=ms8000002038666433, createdTime=Thu Jan 27 21:35:31 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104788, encodeId=06841104e8854, content=摘要需要详细到什么程度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104787, encodeId=9e451104e87f7, content=撰写摘要有什么要点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-06-18 ms6000001341584296

审稿速度:1.0 | 投稿命中率:5.0
偏重的研究方向：肿瘤
经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。

200 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2097970, encodeId=0397209e97070, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：20220428 submitted 20220506 under review 20220622 all reviews complete 20220623 major revision 20220822 revised 20221018 pre-accept 20221101 accept 整个投稿过程不快不慢，编辑态度很好，review意见专业，根据我的经验这个期刊算不上水刊，而且在国外认可度还不错，毕竟不靠发review拉分，唯一的就是版面费不便宜，cell press旗下，看好未来！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Tue Nov 01 23:47:24 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564653, encodeId=ccbd56465366, content=是么？控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高加州理工的工人 2018-05-29 05:21:00 发表: 我刚发一篇.说实话.这个期刊要求真心不高, beContent=控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd1b2506977, createdName=124af5d5m75暂无昵称, createdTime=Wed Dec 19 00:00:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188688, encodeId=af6d11886885a, content=审稿速度:3.0 偏重的研究方向：肝脏纤维化 经验分享：前段时间投了一次。两周后才送外审，接着外审一个半月被拒。感觉审稿较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f226485261, createdName=ms8000002038666433, createdTime=Thu Jan 27 21:35:31 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104788, encodeId=06841104e8854, content=摘要需要详细到什么程度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104787, encodeId=9e451104e87f7, content=撰写摘要有什么要点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-06-22 ms1000001147318258

审稿速度:1.0 | 投稿命中率:50.0
经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。
个人感觉期刊是很有效率和节奏的，值得推荐投稿。

184 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2097970, encodeId=0397209e97070, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：20220428 submitted 20220506 under review 20220622 all reviews complete 20220623 major revision 20220822 revised 20221018 pre-accept 20221101 accept 整个投稿过程不快不慢，编辑态度很好，review意见专业，根据我的经验这个期刊算不上水刊，而且在国外认可度还不错，毕竟不靠发review拉分，唯一的就是版面费不便宜，cell press旗下，看好未来！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Tue Nov 01 23:47:24 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564653, encodeId=ccbd56465366, content=是么？控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高加州理工的工人 2018-05-29 05:21:00 发表: 我刚发一篇.说实话.这个期刊要求真心不高, beContent=控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd1b2506977, createdName=124af5d5m75暂无昵称, createdTime=Wed Dec 19 00:00:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188688, encodeId=af6d11886885a, content=审稿速度:3.0 偏重的研究方向：肝脏纤维化 经验分享：前段时间投了一次。两周后才送外审，接着外审一个半月被拒。感觉审稿较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f226485261, createdName=ms8000002038666433, createdTime=Thu Jan 27 21:35:31 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104788, encodeId=06841104e8854, content=摘要需要详细到什么程度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104787, encodeId=9e451104e87f7, content=撰写摘要有什么要点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-07-01 franky45

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：转录因子
经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。

140 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2097970, encodeId=0397209e97070, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：20220428 submitted 20220506 under review 20220622 all reviews complete 20220623 major revision 20220822 revised 20221018 pre-accept 20221101 accept 整个投稿过程不快不慢，编辑态度很好，review意见专业，根据我的经验这个期刊算不上水刊，而且在国外认可度还不错，毕竟不靠发review拉分，唯一的就是版面费不便宜，cell press旗下，看好未来！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Tue Nov 01 23:47:24 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564653, encodeId=ccbd56465366, content=是么？控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高加州理工的工人 2018-05-29 05:21:00 发表: 我刚发一篇.说实话.这个期刊要求真心不高, beContent=控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd1b2506977, createdName=124af5d5m75暂无昵称, createdTime=Wed Dec 19 00:00:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188688, encodeId=af6d11886885a, content=审稿速度:3.0 偏重的研究方向：肝脏纤维化 经验分享：前段时间投了一次。两周后才送外审，接着外审一个半月被拒。感觉审稿较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f226485261, createdName=ms8000002038666433, createdTime=Thu Jan 27 21:35:31 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104788, encodeId=06841104e8854, content=摘要需要详细到什么程度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104787, encodeId=9e451104e87f7, content=撰写摘要有什么要点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-05-20 术士话剧

偏重的研究方向：骨生物学
经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？

69 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2097970, encodeId=0397209e97070, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：20220428 submitted 20220506 under review 20220622 all reviews complete 20220623 major revision 20220822 revised 20221018 pre-accept 20221101 accept 整个投稿过程不快不慢，编辑态度很好，review意见专业，根据我的经验这个期刊算不上水刊，而且在国外认可度还不错，毕竟不靠发review拉分，唯一的就是版面费不便宜，cell press旗下，看好未来！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Tue Nov 01 23:47:24 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564653, encodeId=ccbd56465366, content=是么？控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高加州理工的工人 2018-05-29 05:21:00 发表: 我刚发一篇.说实话.这个期刊要求真心不高, beContent=控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd1b2506977, createdName=124af5d5m75暂无昵称, createdTime=Wed Dec 19 00:00:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188688, encodeId=af6d11886885a, content=审稿速度:3.0 偏重的研究方向：肝脏纤维化 经验分享：前段时间投了一次。两周后才送外审，接着外审一个半月被拒。感觉审稿较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f226485261, createdName=ms8000002038666433, createdTime=Thu Jan 27 21:35:31 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104788, encodeId=06841104e8854, content=摘要需要详细到什么程度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104787, encodeId=9e451104e87f7, content=撰写摘要有什么要点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2022-01-27 ms8000002038666433

审稿速度:3.0
偏重的研究方向：肝脏纤维化
经验分享：前段时间投了一次。两周后才送外审，接着外审一个半月被拒。感觉审稿较慢。

66 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2097970, encodeId=0397209e97070, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：20220428 submitted 20220506 under review 20220622 all reviews complete 20220623 major revision 20220822 revised 20221018 pre-accept 20221101 accept 整个投稿过程不快不慢，编辑态度很好，review意见专业，根据我的经验这个期刊算不上水刊，而且在国外认可度还不错，毕竟不靠发review拉分，唯一的就是版面费不便宜，cell press旗下，看好未来！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Tue Nov 01 23:47:24 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564653, encodeId=ccbd56465366, content=是么？控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高加州理工的工人 2018-05-29 05:21:00 发表: 我刚发一篇.说实话.这个期刊要求真心不高, beContent=控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd1b2506977, createdName=124af5d5m75暂无昵称, createdTime=Wed Dec 19 00:00:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188688, encodeId=af6d11886885a, content=审稿速度:3.0 偏重的研究方向：肝脏纤维化 经验分享：前段时间投了一次。两周后才送外审，接着外审一个半月被拒。感觉审稿较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f226485261, createdName=ms8000002038666433, createdTime=Thu Jan 27 21:35:31 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104788, encodeId=06841104e8854, content=摘要需要详细到什么程度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104787, encodeId=9e451104e87f7, content=撰写摘要有什么要点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-12-28 Mia

摘要需要详细到什么程度？

94 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2142803, encodeId=afcd2142803d4, content=偏重的研究方向：医学;肿瘤 经验分享：请问各位前辈，under review代表送审了吗？为什么没有收到邮件呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Wed Jun 14 22:11:10 CST 2023, time=2023-06-14, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2097970, encodeId=0397209e97070, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：20220428 submitted 20220506 under review 20220622 all reviews complete 20220623 major revision 20220822 revised 20221018 pre-accept 20221101 accept 整个投稿过程不快不慢，编辑态度很好，review意见专业，根据我的经验这个期刊算不上水刊，而且在国外认可度还不错，毕竟不靠发review拉分，唯一的就是版面费不便宜，cell press旗下，看好未来！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=169, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epp0ckGW2QpfZ3gTrwEibm4B4iaZcibTfdAGuibaGibrWRxUSyIpnHiao7Q61bLCqE7RMvTUbVntiaZCIO2g/132, createdBy=d7a42465704, createdName=苦逼科研仔, createdTime=Tue Nov 01 23:47:24 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=564653, encodeId=ccbd56465366, content=是么？控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高加州理工的工人 2018-05-29 05:21:00 发表: 我刚发一篇.说实话.这个期刊要求真心不高, beContent=控球后卫-姚明 2018-05-29 发表:: 我刚发一篇.说实话.这个期刊要求真心不高, objectType=tool_impact_factor, channel=null, level=null, likeNumber=743, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd1b2506977, createdName=124af5d5m75暂无昵称, createdTime=Wed Dec 19 00:00:00 CST 2018, time=2018-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227145, encodeId=d20d122e1458b, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：肿瘤 经验分享：投Mol cell被编辑建议转投cell reports，20220524转投成功，20220603under review，20220617all review completed。希望好运。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=41b85463819, createdName=ms6000001341584296, createdTime=Sat Jun 18 04:38:13 CST 2022, time=2022-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227996, encodeId=aea5122e99633, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：2021-6-17投稿，2021-6-22送审，2021-7-14审回，2021-10-24修回，2021-11-10接收，2021-12-14定稿。2022-1-11online。 个人感觉期刊是很有效率和节奏的，值得推荐投稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fada6426310, createdName=ms1000001147318258, createdTime=Wed Jun 22 14:50:29 CST 2022, time=2022-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230053, encodeId=319f123005345, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：转录因子 经验分享：在美国，cell reports的牌子很多老板都认的，而且一旦大子刊上不去大家也都欣然选择cell reports。可惜发的东西比较基础，综述少，临床的东西少，特别是新冠的东西没有，所以影响因子上不去。审稿比较快。能不能接收关键看编辑，编辑第一关把控相对比较严，能送外审就希望很大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=140, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Fri Jul 01 23:47:44 CST 2022, time=2022-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1221139, encodeId=736e12211396e, content=偏重的研究方向：骨生物学 经验分享：cell reports投稿需要每个作者都邮件中确认吗？不确认会不会影响审稿速度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKHJoeMDwT8ic73jBc5wUdyQXpogRZA8D2ibh5gOicQ2Vs2xrKjGAdxic8jNfnNICEXZuUNeapibUJooNg/0, createdBy=76982150486, createdName=术士话剧, createdTime=Fri May 20 11:23:16 CST 2022, time=2022-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188688, encodeId=af6d11886885a, content=审稿速度:3.0 偏重的研究方向：肝脏纤维化 经验分享：前段时间投了一次。两周后才送外审，接着外审一个半月被拒。感觉审稿较慢。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f226485261, createdName=ms8000002038666433, createdTime=Thu Jan 27 21:35:31 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104788, encodeId=06841104e8854, content=摘要需要详细到什么程度？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104787, encodeId=9e451104e87f7, content=撰写摘要有什么要点？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=edd01701426, createdName=Gym璨烨, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=)]

2021-12-29 Gym璨烨

撰写摘要有什么要点？

78 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务